Optimizing patient adherence to targeted therapies in renal cell carcinoma. | Clin J Oncol Nurs;18(6): 694-700, 2014 Dec. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Optimizing patient adherence to targeted therapies in renal cell carcinoma.

Creel, Patricia A.

Affiliation

Creel PA; Duke University Medical Center, Durham, NC.

Clin J Oncol Nurs ; 18(6): 694-700, 2014 Dec.

Article in En | MEDLINE | ID: mdl-25427704

Subject(s)
Key words

adverse event management; mammalian target of rapamycin; renal cell carcinoma; tyrosine kinase inhibitor; vascular endothelial growth factor receptor

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Patient Compliance / Kidney Neoplasms / Antineoplastic Agents Aspects: Patient_preference Limits: Humans Language: En Journal: Clin J Oncol Nurs Journal subject: ENFERMAGEM / NEOPLASIAS Year: 2014 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Patient Compliance / Kidney Neoplasms / Antineoplastic Agents Aspects: Patient_preference Limits: Humans Language: En Journal: Clin J Oncol Nurs Journal subject: ENFERMAGEM / NEOPLASIAS Year: 2014 Document type: Article Affiliation country: Country of publication: